详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

The protective role of ginsenoside Rg3 in heart diseases and mental disorders

35| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [2]Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China. [3]Department of Rehabilitation Medicine, Zhongda Hospital, Southeast University, Nanjing, China. [4]Division of Cardiology and Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出处：

DOI：

ISSN：

关键词： ginsenoside Rg3 heart diseases mental disorders heart failure depression

摘要：

Ginsenoside Rg3, a compound derived from Panax ginseng C. A. Mey., is increasingly recognized for its wide range of pharmacological effects. Under the worldwide healthcare challenges posed by heart diseases, Rg3 stands out as a key subject in modern research on Chinese herbal medicine, offering a novel approach to therapy. Mental illnesses are significant contributors to global disease mortality, and there is a well-established correlation between cardiac and psychiatric conditions. This connection is primarily due to dysfunctions in the sympathetic-adrenomedullary system (SAM), the hypothalamic-pituitary-adrenal axis, inflammation, oxidative stress, and brain-derived neurotrophic factor impairment. This review provides an in-depth analysis of Rg3's therapeutic benefits and its pharmacological actions in treating cardiac and mental health disorders respectively. Highlighting its potential for the management of these conditions, Rg3 emerges as a promising, multifunctional therapeutic agent.Copyright © 2024 Shi, Luo, Wei, Xu and Tu.

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2022]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.4 最新[2023版] 5 最新五年平均 5.6 出版当年[2022版] 6.1 出版当年五年平均 5.988 出版前一年[2021版] 4.4 出版后一年[2023版]

第一作者：

第一作者单位： [1]Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [2]Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.

通讯作者：

通讯机构： [1]Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [2]Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma [2]Ginsenoside Rg3 Sensitizes Nasopharyngeal Carcinoma Cells to Radiation by Suppressing Epithelial Mesenchymal Transition [3]Ginsenoside Rg3 Inhibits Migration and Invasion of Nasopharyngeal Carcinoma Cells and Suppresses Epithelial Mesenchymal Transition [4]Ginsenoside Rg3 decreases breast cancer stem-like phenotypes through impairing MYC mRNA stability [5]综合医院门诊躯体形式障碍患者功能损害及相关影响因素 [6]MicroRNAs in cardiovascular diseases [7]Trimetazidine in Heart Failure. [8]DOWN-REGULATION OF LNCRNA-D1 PROMOTES HEART FAILURE DOWN-REGULATION OF LNCRNA-D1 PROMOTES HEART FAILURE [9]Trimetazidine in Heart Failure [10]The promising therapeutic agents for heart diseases: Histone Methyltransferase inhibitors